Tag Archives: Institute for Clinical and Economic Review

Endo coming out of the darkness into the light; contrarians, buy this name.

The News: Endo International Plc (Dublin IRL) on Tuesday (August 8, 2017) lowered its full-year revenue forecast, saying it expected lower sales of branded drugs to add to the pricing… Read more »



Drugmakers’ Pricing Power Helped by Exclusivity Rights: JAMA

The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand-name medicines and changing coverage requirements for government health plans, some… Read more »